Arbutus Biopharma (ABUS) Misses Q3 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.66 million versus the consensus estimate of $4.75 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• JPMorgan Reiterates Overweight Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
• Credo Tech (CRDO) PT Lowered to $245 at Mizuho